FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2023年9月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 北京市春立正達醫療器械股份有限公司 呈交日期: 2023年10月5日 I. 法定/註冊股本變動 本月底法定/註冊股本總額： RMB 383,568,500 第 1 頁 共 6 頁 v 1.0.2 II. 已發行股份變動 | 1. 股份分類 | 普通股 | 股份類別 | H | 於香港聯交所上市 (註1) | 是 | | --- | --- | --- | --- | --- | --- | | 證券代號 | 01858 | 說明 | H股 | | | | 上月底結存 | | 95,140,500 | | | | | 增加 / 減少 (-) | | | 0 | | | | 本月底結存 | | 95,140,500 | | | | | 2. 股份分類 | 普通股 | 股份類別 | A | 於香港聯交所上市 (註1) | 否 | | --- | --- | --- | --- | --- | --- | | 證券代號 | 688236 ...

Regulatory and Market Position - The company holds 102 medical device registrations in China, including 34 Class III, 21 Class II, and 47 Class I registrations, enhancing its market competitiveness [7]. - In the first half of 2023, the company achieved significant progress in obtaining domestic and international registrations, marking the beginning of an accelerated certification phase [8]. - The orthopedic medical device market in China is experiencing growth due to factors such as an aging population and increased healthcare spending [6]. - The orthopedic implant industry is relatively concentrated, with high entry barriers due to strict regulatory measures and high-quality product requirements [6]. - The company actively responds to national procurement policies to ensure stable supply and compliance in the orthopedic joint sector [6]. - The orthopedic implant market is dominated by multinational companies, but domestic firms are expected to increase market share through improved product offerings [6]. Product Development and Innovation - The company aims to expand its product portfolio to meet diverse market and clinical needs, thereby enhancing its overall competitiveness [7]. - The company has established itself as a leader in the domestic orthopedic industry, focusing on the research and development of artificial joint prosthetics, with over 20 years of experience [9]. - As of June 30, 2023, the company has received government funding for multiple R&D projects, including the development of high-quality medical metal powder materials and clinical research on minimally invasive knee joint prosthetics [9]. - The company has successfully launched several new products, including vitamin E high-crosslinked polyethylene hip and knee products, marking a significant advancement in the domestic market [11]. - The company has expanded its product line in the spinal sector, obtaining registration certificates for self-stabilizing cervical interbody fusion devices and artificial vertebral body fixation systems [11]. - In the trauma field, the company has received approvals for multiple products, including bone plates and intramedullary nails, enhancing its orthopedic product offerings [11]. - The company has made significant strides in sports medicine, obtaining registration for seven new products, which will boost sales revenue in this segment [11]. - The company has entered the oral care market, acquiring registration for orthodontic products and maxillofacial surgical devices, establishing a comprehensive oral product line [11]. Financial Performance - As of June 30, 2023, the company's operating revenue was approximately RMB 540.71 million, a decrease of 5.37% compared to RMB 571.39 million in the same period last year [17]. - The company's gross profit for the six months ended June 30, 2023, was approximately RMB 391.41 million, down 8.08% from RMB 425.80 million year-on-year, resulting in a gross margin of 72.39% [19]. - The company achieved a net profit of approximately RMB 125.99 million for the six months ended June 30, 2023, a decline of 19.74% from RMB 156.98 million in the same period last year [25]. - Sales expenses increased by 7.66% to approximately RMB 166.89 million due to the gradual recovery of market activities post-pandemic [20]. - The company's current assets decreased from approximately RMB 957.19 million as of December 31, 2022, to approximately RMB 855.12 million as of June 30, 2023 [26]. - The company reported a total of RMB 154,599,501.79 in special reserves for the period [80]. Research and Development - Research and development expenses for the first half of 2023 amounted to approximately RMB 74.57 million, representing a 3.15% increase from RMB 72.29 million in the previous year, accounting for 13.79% of revenue [22]. - The company plans to enhance its product range by optimizing existing products and investing more resources in new product development, particularly in the orthopedic medical device sector [40]. - The company is focusing on developing customized orthopedic implants, which include traditional and assembled customized joint prosthetics [41]. - The company is committed to enhancing its market share by strengthening production operations and internal management while expanding into new markets [41]. Corporate Governance and Compliance - The board of directors is committed to maintaining high standards of corporate governance, believing it is crucial for protecting shareholder interests and enhancing corporate value [46]. - The company has adopted the "Standard Code" for securities transactions by directors and supervisors, confirming compliance for the six months ending June 30, 2023 [47]. - The audit committee has reviewed the consolidated financial statements for the six months ending June 30, 2023, including the accounting principles and practices used [48]. - The financial report was approved by the board of directors on August 30, 2023, indicating ongoing compliance with accounting standards [86]. Shareholder Information - As of June 30, 2023, Mr. Shi Chunbao holds 113,685,435 A shares, representing 39.42% of the relevant class of share capital and 29.64% of the total share capital [50]. - Ms. Yue Shujun also holds 95,447,900 A shares, representing 33.09% of the relevant class of share capital and 24.88% of the total share capital [50]. - CITIC Securities Co., Ltd. holds 19,750,000 A shares, representing 6.85% of the relevant class of share capital and 5.15% of the total share capital [52]. - FIL Limited holds 7,791,000 H shares, representing 8.19% of the relevant class of share capital and 2.03% of the total share capital [53]. - The total number of issued shares as of June 30, 2023, is 383,568,500, comprising 288,428,000 A shares and 95,140,500 H shares [54]. Assets and Liabilities - As of June 30, 2023, total assets amounted to RMB 3,472,457,994.37, an increase from RMB 3,409,766,690.91 as of December 31, 2022, reflecting a growth of approximately 1.84% [57]. - Total liabilities reached RMB 745,055,516.20, up from RMB 690,066,911.19, marking an increase of around 7.97% [60]. - Shareholders' equity totaled RMB 2,727,402,478.17, compared to RMB 2,719,699,779.72 at the end of 2022, showing a slight increase of about 0.1% [60]. - The company's long-term liabilities, including lease liabilities, were reported at RMB 625,860.19, with deferred income tax liabilities increasing to RMB 10,439,311.12 from RMB 7,879,291.52 [58]. - The total current liabilities increased to RMB 650,355,916.53 from RMB 595,804,539.93, representing a growth of approximately 9.15% [59]. Cash Flow and Investments - The net cash outflow from operating activities was approximately RMB 38.97 million as of June 30, 2023, mainly due to increased cash received from sales [34]. - The net cash flow from operating activities is negative at RMB -38,971,893.80, an improvement from RMB -81,512,729.59 in the same period last year [71]. - The net cash flow from investing activities is RMB -63,934,501.16, an improvement from RMB -510,359,121.29 in the previous year [72]. - Cash inflow from investment activities totaled RMB 1,537,695,421.37, compared to RMB 926,741,308.22 in the previous year, indicating a significant increase [75]. - The company redeemed all structured deposit products with a total investment of RMB 30 million from Bank of Beijing, yielding an actual return of RMB 313.27 thousand at an annualized return of 3.15% [36]. Inventory and Receivables - The company reported a total inventory at the end of the period is RMB 408,488,947.36, an increase from RMB 280,772,410.70 at the beginning of the period, representing a growth of 45.5% [173]. - The raw materials inventory increased to RMB 152,517,933.68 from RMB 85,077,518.73, reflecting an increase of 79.2% [173]. - The finished goods inventory at the end of the period is RMB 199,661,078.26, up from RMB 142,731,746.75, indicating a rise of 39.7% [173]. - Accounts receivable at the end of the period totaled RMB 578,927,472.41, up from RMB 488,746,494.02, indicating an increase of approximately 18.5% [155]. - The provision for bad debts was RMB 60,772,707.03, which is 9.50% of the total accounts receivable, compared to 51,949,099.75 and 9.61% at the beginning of the period [156]. Taxation and Deferred Tax - The company maintains a corporate income tax rate of 15%, benefiting from high-tech enterprise status valid until 2023 [151]. - The total deferred tax assets at the end of the period amounted to CNY 8,156,997.68, an increase from CNY 3,130,616.33 at the beginning of the period, reflecting a growth of approximately 160% [197]. - The total deferred tax liabilities at the end of the period were CNY 10,439,311.12, up from CNY 7,879,291.52 at the beginning, representing an increase of about 32% [198]. Accounting Policies and Practices - The financial statements are prepared in accordance with the Chinese Accounting Standards, ensuring transparency and accuracy in financial reporting [86]. - The company recognizes revenue when the customer obtains control of the related goods or services, which is determined by specific indicators such as the transfer of legal ownership and the acceptance of goods [134]. - The company assesses the useful life of intangible assets based on contractual or legal rights without a clear term, and reviews these annually [125]. - The company recognizes expected credit losses for financial assets measured at amortized cost and those classified at fair value through other comprehensive income, including receivables and lease receivables [106].

重要内容提示： 证券代码：688236 证券简称：春立医疗 公告编号：2023-038 北京市春立正达医疗器械股份有限公司 关于召开 2023 年第一次临时股东大会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、 召开会议的基本情况 （一） 股东大会类型和届次 2023 年第一次临时股东大会 召开日期时间：2023 年 10 月 10 日 14 点 00 分 召开地点：北京市通州区通州经济开发区南区鑫觅西二路 10 号公司会议室 （五） 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自 2023 年 10 月 10 日 至 2023 年 10 月 10 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 股东大会召开日期：2023年10月10日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票 系统 （二） 股东大会召集人：董事会 （三） 投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结 合的方式 （四） ...

北京市春立正达医疗器械股份有限公司 2023 年第一次临时股东大会会议资料 证券代码：688236 证券简称：春立医疗 北京市春立正达医疗器械股份有限公司 2023 年第一次临时股东大会 会议资料 二〇二三年九月 1 北京市春立正达医疗器械股份有限公司 2023 年第一次临时股东大会会议资料 2023 年第一次临时股东大会会议资料 目录 | 2023 年第一次临时股东大会会议须知 | | 3 | | --- | --- | --- | | 2023 年第一次临时股东大会会议议程 | | 5 | | 议案一：《关于部分募投项目变更的议案》 | | 6 | 2 北京市春立正达医疗器械股份有限公司 2023 年第一次临时股东大会会议资料 2023 年第一次临时股东大会会议须知 为了维护全体股东的合法权益，确保股东大会的正常秩序和议事效率，保证 大会的顺利进行，根据《中华人民共和国公司法》《中华人民共和国证券法》《上 市公司股东大会规则（2022 年修订）》以及《公司章程》、《股东大会议事规则》 等相关规定，特制定北京市春立正达医疗器械股份有限公司（以下简称"公司"） 2023 年第一次临时股东大会会议须知： 一、为 ...

华泰联合证券有限责任公司 关于北京市春立正达医疗器械股份有限公司 2023 年半年度持续督导跟踪报告 | 保荐机构名称： | 被保荐公司简称： | | --- | --- | | 华泰联合证券有限责任公司 | 北京市春立正达医疗器械股份有限公司 | | 保荐代表人姓名：张畅 | 联系电话：010-56839300 | | 保荐代表人姓名：茹涛 | 联系电话：021-38966546 | 根据《证券法》《证券发行上市保荐业务管理办法》和《上海证券交易所科 创板股票上市规则》等有关法律、法规的规定，华泰联合证券有限责任公司（以 下简称"华泰联合证券"或"保荐机构"）作为北京市春立正达医疗器械股份有 限公司（以下简称"春立医疗"、"公司"或"发行人"）首次 A 股公开发行股 票的保荐机构，对春立医疗进行持续督导，并出具本持续督导跟踪报告： 一、保荐机构和保荐代表人发现的问题及整改情况 无 二、重大风险事项 （一）经营风险 1、核心材料依赖境外单一供应商的风险 公司陶瓷关节假体产品所用到的陶瓷球头、陶瓷内衬均自 CeramTec GmbH 采购。CeramTec GmbH 是一家总部位于德国的先进陶瓷材料供应商，包括 ...

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2023年8月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 北京市春立正達醫療器械股份有限公司 呈交日期: 2023年9月5日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 | 01858 | 說明 | H股 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 95,140,500 | RMB | | 1 RMB | | 95,140,500 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 95,140,500 | RMB | | 1 RMB | | 95,140,500 | | 2. 股份分類 | 普通股 | 股份類別 | A | ...

Financial Performance - The company reported a total revenue of RMB 1.5 billion for the first half of 2023, representing a year-on-year increase of 20%[14]. - Future guidance estimates a revenue growth of 25% for the full year 2023, driven by new product launches and market expansion[14]. - The company’s revenue for the first half of 2023 decreased by 5.37% to approximately ¥540.71 million, primarily due to price reductions from "volume-based procurement" affecting product sales[193]. - Operating costs increased by 2.55% to approximately ¥149.30 million, driven by higher sales volumes resulting from "volume-based procurement"[193]. - Research and development expenses rose by 3.16% to approximately ¥74.57 million, reflecting the company's commitment to new product and technology development[193]. - Accounts receivable at the end of the reporting period amounted to ¥578.93 million, an increase of ¥488.75 million compared to the beginning of the period, indicating potential cash flow risks[185]. - Inventory increased by 49.12% to approximately ¥387.39 million, as the company stocked products in response to market demand[197]. - Management expenses increased by 22.59% to approximately ¥18.96 million, primarily due to increased depreciation of fixed assets[193]. - The company reported a net cash outflow from operating activities of approximately -¥38.97 million, an improvement from -¥81.51 million in the previous year[193]. Research and Development - The company is investing RMB 200 million in R&D for advanced medical technologies over the next two years[14]. - The total R&D investment amounted to 74,572,384.70, representing 13.79% of total revenue, an increase of 1.14 percentage points compared to the previous period[27]. - The R&D investment capitalization ratio remains at 0.00%, indicating that all R&D expenses are currently expensed[27]. - The company is currently in the clinical trial phase for improved hip joint series products, with a total investment of 9,693.46, including 850.58 in the current period[29]. - The company is developing innovative single-compartment knee joint prosthetics to minimize nerve damage, enhancing the longevity of the prosthetics[29]. - The company is actively investing in R&D for new materials such as porous tantalum and magnesium alloys, aiming to enhance its product line and respond to national procurement policies[178]. - The company emphasizes continuous R&D investment to enhance its technological capabilities and product offerings, reflecting its commitment to innovation[157]. - The company has filed 93 new patent applications this period, with 73 patents granted, bringing the total to 1,000 applications and 528 granted patents[153]. - The number of R&D personnel increased to 462, accounting for 33.50% of the total workforce, up from 23.28% the previous year[166]. Product Development and Innovation - The company plans to launch three new orthopedic products by Q4 2023, targeting a market expansion of 10% in the orthopedic device sector[14]. - The company is in the registration phase for new product innovations, including knee and shoulder joint prosthetics, to enhance market competitiveness[29]. - The company has developed a range of high-end medical devices, including various orthopedic implant products, which are classified as Class III medical devices due to their significant impact on human health[86]. - The company has developed a full range of spinal internal fixation systems and is expanding its product line to include orthopedic robots and other advanced technologies[90]. - The company has developed a comprehensive oral ecosystem solution, covering orthodontics, implants, and maxillofacial surgery[151]. - The company has achieved significant advancements in sports medicine, obtaining registration for seven new products in this field[151]. - The company has obtained 102 medical device registration certificates in China, including 34 Class III, 21 Class II, and 47 Class I devices, enhancing its product line and market competitiveness[152]. - The company has received registration certificates in 19 countries, including Ukraine, South Korea, and Mexico, indicating strong international market competitiveness[153]. Market Position and Strategy - The company is a leading domestic enterprise in the orthopedic implant medical device sector, with a comprehensive product line and strong market competitiveness[89]. - The orthopedic implant market in China is expected to maintain a continuous growth momentum, driven by improved medical conditions and social security systems[85]. - The company is focusing on expanding its market share in the spinal and sports medicine product lines while maintaining its position in the joint product line[178]. - The company is actively developing international markets and enhancing its international business team and marketing investments[89]. - The company is adapting to changes in sales models due to policies like "volume-based procurement," which may impact traditional revenue streams[181]. Quality Control and Compliance - The company has established a strict quality control system to ensure the safety and effectiveness of orthopedic medical devices, which is crucial for expanding market share and establishing competitive advantages[171]. - The company’s R&D is managed according to ISO 13485 and ISO 9001 standards, ensuring high-quality product development processes[109]. - The company has obtained ISO 9001 and ISO 13485 quality management system certifications, ensuring product reliability and stability in the market[176]. Risks and Challenges - The company is facing risks related to the supply of ceramic materials from CeramTec GmbH, which may affect production due to international trade disputes[36]. - The company faces risks related to market competition, particularly from international brands like Johnson & Johnson and Medtronic, which dominate the domestic market[182]. - The company is actively monitoring the impact of national procurement policies on product pricing and is enhancing its product innovation capabilities to mitigate risks[186]. - The company faced risks from reliance on a single overseas supplier for core materials, which could impact operations if supply issues arise[186].

Financial Performance - For the six months ended June 30, 2023, the company reported operating revenue of RMB 540,706,888.57, a significant increase from RMB 571,391,616.43 in the same period of 2022[6]. - The company's operating profit for the same period was RMB 138,459,630.64, compared to RMB 174,637,494.77 in 2022, indicating a decrease in profitability[6]. - The net profit for the six months ended June 30, 2023, was RMB 125,985,161.70, a decrease of approximately 19.7% compared to RMB 156,982,496.60 for the same period in 2022[8]. - The net profit attributable to shareholders of the parent company was RMB 126,077,038.00, down from RMB 156,982,496.60, indicating a decline of about 19.7% year-over-year[9]. - Basic and diluted earnings per share for the six months ended June 30, 2023, were both RMB 0.33, compared to RMB 0.41 for the same period in 2022, reflecting a decrease of approximately 19.5%[10]. - The total comprehensive income attributable to shareholders of the parent company for the period was RMB 125,985,161.70, compared to RMB 156,982,496.60 in the previous year, marking a decline of around 19.7%[10]. - The company's main operating revenue for the first half of 2023 was RMB 540,241,563.44, compared to RMB 569,856,989.16 in the same period of 2022, indicating a decline of about 5.23%[24]. - The company's gross profit for the same period was approximately RMB 391.41 million, down 8.08% from RMB 425.80 million year-on-year, resulting in a gross margin of 72.39%, a decline of 2.13%[46]. Assets and Liabilities - Total assets as of June 30, 2023, amounted to RMB 3,472,457,994.37, up from RMB 3,409,766,690.91 at the end of 2022[2]. - The total liabilities increased to RMB 745,055,516.20 as of June 30, 2023, compared to RMB 690,066,911.19 at the end of 2022[4]. - The company’s cash and cash equivalents totaled RMB 855,124,538.98 as of June 30, 2023, compared to RMB 957,193,661.02 at the end of 2022[2]. - The company’s accounts receivable increased to RMB 578,927,472.41 as of June 30, 2023, from RMB 488,746,494.02 at the end of 2022, reflecting a growth of approximately 18.5%[2]. - The total accounts payable as of June 30, 2023, was RMB 232,142,733.03, slightly down from RMB 237,786,563.39 at the end of 2022, indicating a decrease of about 2.7%[19]. - The company's current assets decreased from approximately RMB 957.19 million as of December 31, 2022, to RMB 855.12 million as of June 30, 2023[53]. - The company's net current assets decreased from approximately RMB 2,183.28 million as of December 31, 2022, to approximately RMB 2,171.08 million as of June 30, 2023, primarily due to an increase in current liabilities during the period[60]. Research and Development - Research and development expenses for the first half of 2023 were RMB 74,572,384.70, slightly higher than RMB 72,289,835.94 in the same period of 2022[6]. - The company has significantly increased its R&D investment, resulting in a large number of domestic and international registrations obtained in the first half of 2023[34]. - The company plans to establish a product R&D center at the Daxing New Production Base, which will include departments for joint prosthetics, spine products, orthopedic trauma products, and a biomechanics center[68]. - The company is focused on developing standard joint prosthetic products, advanced customized joint prosthetic products, orthopedic robots, spine products, trauma, sports medicine products, PRP products, and oral products[68]. Market and Growth Strategy - The company plans to continue its market expansion and product development strategies to enhance future growth prospects[11]. - The orthopedic medical device market in China is experiencing growth due to factors such as an aging population and increased healthcare spending[32]. - The company aims to enhance its market share by improving its product portfolio and expanding its marketing network[33]. - The company is actively expanding its product line to meet diverse market and clinical needs, enhancing its overall competitiveness[34]. - The company aims to achieve a targeted annual growth rate of 5% in the upcoming fiscal year[63]. Compliance and Governance - The financial statements were prepared based on the going concern assumption, adhering to the applicable disclosure requirements under Hong Kong company regulations[12]. - The company has adopted new and revised Chinese accounting standards effective as of June 30, 2023, to ensure compliance with regulatory requirements[12]. - The audit committee has reviewed the consolidated financial statements for the six months ended June 30, 2023, including the accounting principles applied[74]. - The company is committed to maintaining high standards of corporate governance to protect shareholder interests and enhance corporate value[72]. Employee and Talent Management - As of June 30, 2023, the company employed approximately 1,379 employees, with total salary and related costs amounting to approximately RMB 135.89 million[70]. - The company continues to implement its existing talent development policies and has established an effective incentive mechanism to motivate employees[69]. International Expansion - The company obtained registration certificates for 19 countries, including Ukraine, South Korea, and Mexico, enhancing its international sales capabilities[41]. - The company has completed several clinical research projects and has received approvals for various innovative medical materials and products[36]. - The company is committed to maintaining its leading position in the domestic market while strengthening its international business development and market promotion efforts[66].

北京市春立正达医疗器械股份有限公司 关于召开 2023 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 投资者可于 2023 年 08 月 24 日(星期四) 至 08 月 30 日(星期三)16:00 前登录上证 路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 ir@clzd.com 进行提问。公 司将在说明会上对投资者普遍关注的问题进行回答。 北京市春立正达医疗器械股份有限公司（以下简称"公司"）将于 2023 年 8 月 31 日发布公司 2023 年半年度报告，为便于广大投资者更全面深入地了解公司 2023 年半年 度经营成果、财务状况，公司计划于 2023 年 08 月 31 日上午 10:00-11:00 举行 2023 年 半年度业绩说明会，就投资者关心的问题进行交流。 证券代码：688236 证券简称：春立医疗 公告编号：2023-032 财务总监：李玉梅女士 （如有特殊情况，参会人员可能进行调整） 四、 投资者参加方式 一、 说明会类型 本次投资者说明会以网络互 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 表 明 概 不 就 因 本 公 告 全 部 或 任 何 部 分 內 容 而 產 生 或 因 依 賴 該 等 內 容 而 引 致 的 任 何 損 失 承 擔 任 何 責 任。 北京市春立正達醫療器械股份有限公司 Beijing Chunlizhengda Medical Instruments Co., Ltd.* 北京市春立正達醫療器械股份有限公司（「本公司」）之董事會（「董事會」）謹此宣 佈將於2023年8月30日（星 期 三）舉 行 董 事 會 會 議，藉 以（其 中 包 括）批准本公司及 其附屬公司截至2023年6月30日止六個月之中期業績公佈及考慮派付中期股息 （如 有）。 代表董事會 北京市春立正達醫療器械股份有限公司 史文玲 董事長 中 國，北 京，2023年8月18日 截 至 本 公 告 日 期，執 行 董 事 為 史 春 寶 先 生、岳 術 俊 女 士、史 文 玲 女 士 及 解 鳳 寶 先 生；非 執 行 董 事 為 王 鑫 先 生；及 獨 立 ...